EMA Sides with Former Executive Director - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Sides with Former Executive Director


ePT--the Electronic Newsletter of Pharmaceutical Technology

In a press release on Mar. 21, 2011, the EMA Management Board gave its approval for the current activities of former executive director Thomas Lönngren.

Lönngren, who stepped down on Dec. 31, 2010, came under fire from several organisations that claimed that his move to a new position as an advisor to the private pharmaceutical sector might have breached conflict-of-interest rules. In particular, the groups' letter, dated Feb. 25, 2010, expressed concern that “there was no ‘cooling off’ period between his former and current employment."

Though the EMA Management Board approved Lönngren’s recent appointments, it was quick to state that it took the agency’s role in protecting the public interest and maintaining a good reputation seriously.

The board based its decision on two factors: “Firstly, whether any activity risked the misuse of confidential or privileged information gained during his leadership of the Agency and secondly whether any activity risked improper influence on decisions taken by the Agency.” The board concluded that no risk was posed, but expressed regret at Lönngren's tardiness in notifying it of his new appointments.

Despite the approval, the board imposed a set of limitations that will remain in place for a period of two years effective immediately. The limitations forbid Lönngren to take the following actions:

  • Taking managerial or executive positions in the pharmceutical industry
  • Providing product-related advice on activities within EMA’s remit
  • Having contact with agency staff or committee members in a professional context
  • Representing or accompanying third parties at meetings with the agency

By making its decision and supporting documents public, the EMA hopes to ensure accountability and allay the concerns that five European public-health and transparency campaigners raised.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here